Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of PF-07258669 in Healthy Adults
NCT04628793Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07258669 in Malnutrition, cachexia and anorexia nervosa (AN) (3 cohorts), sponsored by Pfizer. Primary endpoints: Treatment Emergent Adverse Events, Clinical Laboratory Abnormalities and 3 more. Started Mar 2021; status: completed.
02
Drugs
PF-07258669
03
Conditions
Malnutritioncachexiaanorexia nervosa (AN)
Beyond the preview
Go deeper on NCT04628793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04628793.